跳至主要内容
临床试验/EUCTR2015-005045-31-NL
EUCTR2015-005045-31-NL进行中(未招募)1 期

Switching to Tenofovir Alafenamide Fumarate or ABACavir in patients with Tenofovir Disoproxil Fumarate associated eGFR decline. A randomized clinical trial. - BACTAF

Erasmus MC0 个研究点开始时间: 2016年2月25日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
Erasmus MC

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 18 years or older
  • HIV-positive with HIV-RNA <50 c/ml for at least 6 months
  • Stable on TDF/FTC or TDF/3TC for at least 12 months, in combination with a 3rd antiretroviral agent
  • Confirmed/probable TDF-related eGFR-decline with absence of other causes of eGFR-decline.
  • HLA-B5701 allele negative
  • General medication and condition does not interfere with trial procedure.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 80
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Chronic hepatitis B or C
  • Symptomatic arterial disease e.g. a history of coronary artery disease, ischemic cerebrovascular accident or claudication intermittens in medical history
  • Not meeting all inclusion-criteria as mentioned above

研究者

发起方
Erasmus MC

相似试验

已完成
3 期
Switching to Tenofovir Alafenamide Fumarate or ABACavir in patients with Tenofovir Disoproxil Fumarate associated eGFR decline. A randomized clinical trial.AIDSHIV1002146010047438
NL-OMON46033Erasmus MC, Universitair Medisch Centrum Rotterdam80
进行中(未招募)
1 期
Substitution current ARV therapy by BIKTARVY in hiv infected patients over 65 years oldHIV-1-infected patientAge > 65 years oldPlasma HIV RNA = 50 copies/mL for = 6 months: one blip between 50 et 200 cp/ml is allowed in the last 6 months before screening.Currently receiving an antiretroviral regimen containing a booster, ritonavir or cobicistat No resistance mutation to integrase inhibitors on cumulative HIV RNA genotype. Patient enrolled in or a beneficiary of a Social Security program Informed consent form signed
EUCTR2019-002843-81-FRIMEA50
招募中
不适用
Switching to tenofovir alafenamide on efficacy, safety, and tolerability for nucleos(t)ide analogue-experienced patients with chronic hepatitis BChronic hepatitis B
JPRN-UMIN000031903Kyushu University400
已完成
不适用
Switching from Lopinavir/Ritonavir Plus Tenofovir and Emtricitabine (or Lamivudine) to Darunavir (Prezista) and Raltegravir to Evaluate Renal FunctioHIV infections, AIDS, HIV-1
JPRN-UMIN000005116AIDS Clinical Center at National Center for Global Health and Medicine54
进行中(未招募)
4 期
Switching From TDF-based Antiretroviral Therapy Regimens to B/F/TAF in Virally Suppressed Adults With HIV-1 InfectionHIV-1-infection
NCT05122754Shanghai Public Health Clinical Center150